Kala Pharmaceuticals Stock Analysis

KALA Stock  USD 5.96  0.04  0.67%   
Kala Pharmaceuticals is undervalued with Real Value of 12.1 and Target Price of 30.0. The main objective of Kala Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Kala Pharmaceuticals is worth, separate from its market price. There are two main types of Kala Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Kala Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Kala Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

Kala Stock Analysis Notes

About 26.0% of the company shares are owned by institutional investors. The book value of Kala Pharmaceuticals was now reported as 2.37. The company recorded a loss per share of 14.56. Kala Pharmaceuticals had not issued any dividends in recent years. The entity had 1:50 split on the 21st of October 2022. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts. Kala Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 192 people. To find out more about Kala Pharmaceuticals contact Mark Iwicki at 781 996 5252 or learn more at https://www.kalarx.com.

Kala Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kala Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kala Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kala Pharmaceuticals generated a negative expected return over the last 90 days
Kala Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (42.2 M) with profit before overhead, payroll, taxes, and interest of 1.33 M.
Kala Pharmaceuticals currently holds about 44.57 M in cash with (27.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 30.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Kala Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Latest headline from investing.com: Kala Bio CEO sells shares worth over 45,000

Kala Pharmaceuticals Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kala Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Kala Largest EPS Surprises

Earnings surprises can significantly impact Kala Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-29
2023-12-31-3.62-3.180.4412 
2023-08-04
2023-06-30-3.19-4.36-1.1736 
2023-11-13
2023-09-30-2.15-3.41-1.2658 
View All Earnings Estimates

Kala Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Kala Pharmaceuticals' ESG score is a quantitative measure that evaluates Kala Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Kala Pharmaceuticals' operations that may have significant financial implications and affect Kala Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Kala Stock Institutional Investors

Shares
Morgan Stanley - Brokerage Accounts2024-03-31
1.4 K
Covestor Ltd2024-03-31
K
Banque Cantonale Vaudoise2024-03-31
808
Compagnie Lombard, Odier Sca2024-03-31
400
Citigroup Inc2024-03-31
296
Advisor Group Holdings, Inc.2024-03-31
241
Cwm, Llc Duplicate2024-03-31
200
Steward Partners Investment Advisory, Llc2024-03-31
120
Bank Of America Corp2024-03-31
111
Baker Bros Advisors Lp2024-03-31
266.6 K
Millennium Management Llc2024-03-31
133.4 K
Note, although Kala Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kala Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.9 M.

Kala Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.75)(0.79)
Return On Capital Employed(0.82)(0.86)
Return On Assets(0.75)(0.79)
Return On Equity(5.62)(5.34)

Management Efficiency

Kala Pharmaceuticals has return on total asset (ROA) of (0.4078) % which means that it has lost $0.4078 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6261) %, meaning that it created substantial loss on money invested by shareholders. Kala Pharmaceuticals' management efficiency ratios could be used to measure how well Kala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of June 18, 2024, Return On Tangible Assets is expected to decline to -0.79. In addition to that, Return On Capital Employed is expected to decline to -0.86. At present, Kala Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 8.84, whereas Total Assets are forecasted to decline to about 53.2 M.
Last ReportedProjected for Next Year
Book Value Per Share 3.09  2.93 
Tangible Book Value Per Share 3.09  2.93 
Enterprise Value Over EBITDA(0.06)(0.07)
Price Book Value Ratio 2.27  1.81 
Enterprise Value Multiple(0.06)(0.07)
Price Fair Value 2.27  1.81 
Enterprise Value27.4 M29.6 M
The analysis of Kala Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Kala Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Kala Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
(1.97)
Return On Assets
(0.41)
Return On Equity
(2.63)

Technical Drivers

As of the 18th of June 2024, Kala Pharmaceuticals secures the Standard Deviation of 3.15, mean deviation of 2.01, and Risk Adjusted Performance of (0.04). Kala Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.

Kala Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Kala Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Kala Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Kala Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kala Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kala Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kala Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kala Pharmaceuticals Predictive Daily Indicators

Kala Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kala Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kala Pharmaceuticals Corporate Filings

8K
12th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
3rd of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
30th of May 2024
Other Reports
ViewVerify
8K
14th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
29th of April 2024
Other Reports
ViewVerify
19th of April 2024
Other Reports
ViewVerify
8K
29th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
26th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Kala Pharmaceuticals Forecast Models

Kala Pharmaceuticals' time-series forecasting models are one of many Kala Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kala Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Kala Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kala Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kala shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kala Pharmaceuticals. By using and applying Kala Stock analysis, traders can create a robust methodology for identifying Kala entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(10.36)(10.88)
Operating Profit Margin(18.81)(19.75)
Net Loss(0.05)(0.05)
Gross Profit Margin 0.39  0.59 

Current Kala Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kala analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kala analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
30.0Strong Buy3Odds
Kala Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kala analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kala stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kala Pharmaceuticals, talking to its executives and customers, or listening to Kala conference calls.
Kala Analyst Advice Details

Kala Stock Analysis Indicators

Kala Pharmaceuticals stock analysis indicators help investors evaluate how Kala Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kala Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kala Pharmaceuticals stock analysis, traders can identify Kala Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow70.5 M
Long Term Debt34.2 M
Common Stock Shares Outstanding2.4 M
Total Stockholder Equity7.5 M
Property Plant And Equipment Net2.8 M
Cash And Short Term Investments50.9 M
Cash50.9 M
Accounts Payable919 K
Net Debt-14.6 M
50 Day M A6.7061
Total Current Liabilities8.3 M
Other Operating Expenses39.2 M
Non Current Assets Total3.1 M
Non Currrent Assets Other301 K
Stock Based Compensation7.5 M

Complementary Tools for Kala Stock analysis

When running Kala Pharmaceuticals' price analysis, check to measure Kala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kala Pharmaceuticals is operating at the current time. Most of Kala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities